Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cyteir Therapeutics, Inc.CYT · Entity 92707 | Director | February 03, 2023 | February 07, 2023 |
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | Chief Medical Officer | August 01, 2022 | August 01, 2022 |
| Lantheus Holdings, Inc.LNTH · Entity 690 | Chief Medical Officer | June 17, 2024 | June 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cyteir Therapeutics, Inc.
Report date February 03, 2023 · Filed February 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03 | Direct | 14,150 |
Reported balance
After 2023-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-03 · Grant · Acquired 14,150 · Balance 14,150 F1: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.
Dianthus Therapeutics, Inc. /DE/
Report date August 01, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2032-07-31 | Direct | 75,000 |
Reported balance
After 2022-08-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-01 · Grant · Acquired 75,000 · Balance 75,000 F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022.
Lantheus Holdings, Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,076 |
Reported balance
After 2024-06-17 transaction · row 1
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 9,076 · Balance 9,076 F1: Consists of 9,076 restricted stock units that vest in equal installments over a three-year period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $82.63 · Expires 2034-06-17 | Direct | 16,188 |
Reported balance
After 2024-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-17 · Grant · Acquired 16,188 · Balance 16,188 F2: The option vests in three equal annual installments beginning on June 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 9,076 restricted stock units that vest in equal installments over a three-year period.
F2: The option vests in three equal annual installments beginning on June 17, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.20 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 133,000 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 35,055 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2024 Filed Jun 20, 2024 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 16,188 | $0.00 Strike: $82.63 | $0.00 |
DisclosureSEC source: 0000950170-24-075627 · ownership.xml · derivative · entry 2 Humphrey Jeffrey · CIK 0001816944 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,188 Underlying: Common Stock · 16,188 shares Expires 2034-06-17 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 17, 2025. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 9,076 | $82.63 | $749,949.88 |
DisclosureSEC source: 0000950170-24-075627 · ownership.xml · nonDerivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,076 F1 · kind: Consists of 9,076 restricted stock units that vest in equal installments over a three-year period. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 16:43 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to Buy) · Derivative | 14,150 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-23-007544 · doc4.xml · derivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires 2033-02-03 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 21:14 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0000899243-22-027272 · doc4.xml · derivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-07-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022. Read SEC document |
| May 17, 2022 Filed May 19, 2022 16:23 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000899243-22-018819 · doc4.xml · derivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable in three equal installments, each installment vesting every six months, over the 18 months following the vesting commencement date. The vesting commencement date is May 15, 2022. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 17:00 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to Buy) · Derivative | 2,358 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0000899243-22-007648 · doc4.xml · derivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,358 Underlying: Common Stock · 2,358 shares Expires 2032-02-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on February 22, 2023, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 17:22 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0000899243-22-006824 · doc4.xml · derivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 16:35 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to Buy) · Derivative | 28,300 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0000899243-21-048612 · doc4.xml · derivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,300 Underlying: Common Stock · 28,300 shares Expires 2031-12-15 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of December 15, 2021, subject to the Reporting Person's continued service to the board of directors of the Issuer through the applicable vesting date. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 16:34 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0000899243-21-038823 · doc4.xml · derivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-09-30 F1 · derivative.exercise_date: This option shall vest and become exerciseable over four years, with 25% of this option vesting on October 1, 2022, and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 18:45 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Disposition to issuerStock Options (Right to buy) · Derivative | 35,055 | Not disclosed Strike: $35.50 | Not disclosed |
DisclosureSEC source: 0001562180-21-004988 · primarydocument.xml · derivative · entry 2 Humphrey Jeffrey · CIK 0001816944 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,055 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 18:45 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Disposition to issuerStock Option (Right to Buy) · Derivative | 133,000 | Not disclosed Strike: $30.20 | Not disclosed |
DisclosureSEC source: 0001562180-21-004988 · primarydocument.xml · derivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 16:53 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 35,055 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001562180-21-001265 · primarydocument.xml · derivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,055 Underlying: Common Stock · 35,055 shares Expires 2031-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2021, and the shares underlying the option vest in equal quarterly installments through February 16, 2025, subject to continued service. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 16:48 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Options (Right to buy) · Derivative | 133,000 | $0.00 Strike: $30.20 | $0.00 |
DisclosureSEC source: 0001562180-20-005078 · primarydocument.xml · derivative · entry 1 Humphrey Jeffrey · CIK 0001816944 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,000 Underlying: Common Stock · 133,000 shares Expires 2030-07-06 F1 · derivative.exercise_date: This option was granted on July 7, 2020, and is scheduled to vest as to 25% of the shares underlying the option on July 7, 2021 with the remainder vesting in equal quarterly installments through July 7, 2024, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.